4.6 Review

Cardiovascular Magnetic Resonance for Patients With COVID-19

Journal

JACC-CARDIOVASCULAR IMAGING
Volume 15, Issue 4, Pages 685-699

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jcmg.2021.08.021

Keywords

cardiovascular magnetic resonance; COVID-19; ischemia; multisystem inflammatory syndrome; myocardial injury; myocarditis; SARS-CoV-2

Funding

  1. Bayer AG
  2. Neosoft
  3. Medis
  4. Siemens
  5. National Institute for Health Research Biomedical Research Centre at Barts
  6. British Heart Foundation
  7. British Heart Foundation Centre of Research Excellence, Oxford
  8. National Institute for Health Research Oxford Biomedical Research Centre at Oxford University Hospitals NHS Foundation Trust
  9. British Heart Foundation Clinical Research Training Fellowship [FS/17/81/33318]

Ask authors/readers for more resources

COVID-19 is associated with myocardial injury, and cardiovascular magnetic resonance (CMR) is a noninvasive diagnostic tool that can evaluate the cardiac function and tissue abnormalities in patients recovering from COVID-19. Studies have reported CMR abnormalities in up to 60% of recovered COVID-19 patients, including functional impairment, myocardial tissue abnormalities, late gadolinium enhancement, or pericardial abnormalities.
COVID-19 is associated with myocardial injury caused by ischemia, inflammation, or myocarditis. Cardiovascular magnetic resonance (CMR) is the noninvasive reference standard for cardiac function, structure, and tissue composition. CMR is a potentially valuable diagnostic tool in patients with COVID-19 presenting with myocardial injury and evidence of cardiac dysfunction. Although COVID-19-related myocarditis is likely infrequent, COVID-19-related cardiovascular histopathology findings have been reported in up to 48% of patients, raising the concern for long-term myocardial injury. Studies to date report CMR abnormalities in 26% to 60% of hospitalized patients who have recovered from COVID-19, including functional impairment, myocardial tissue abnormalities, late gadolinium enhancement, or pericardial abnormalities. In athletes post-COVID-19, CMR has detected myocarditis-like abnormalities. In children, multisystem inflammatory syndrome may occur 2 to 6 weeks after infection; associated myocarditis and coronary artery aneurysms are evaluable by CMR. At this time, our understanding of COVID-19-related cardiovascular involvement is incomplete, and multiple studies are planned to evaluate patients with COVID-19 using CMR. In this review, we summarize existing studies of CMR for patients with COVID-19 and present ongoing research. We also provide recommendations for clinical use of CMR for patients with acute symptoms or who are recovering from COVID-19. Crown Copyright (C) 2022 Published by Elsevier on behalf of the American College of Cardiology Foundation. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available